Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person25
Barinthus Biotherapeutics plc.
Company
BICYCLE THERAPEUTICS PLC
Company
Akari Therapeutics Plc
Company
Bolt Biotherapeutics, Inc.
Company
SAB Biotherapeutics, Inc.
Company
Autolus Therapeutics plc
Company
Protalix BioTherapeutics, Inc.
Company
Atara Biotherapeutics, Inc.
Company
IOVANCE BIOTHERAPEUTICS, INC.
Company
Arcutis Biotherapeutics, Inc.
Company
Artiva Biotherapeutics, Inc.
Company
Calidi Biotherapeutics, Inc.
Company
Latigo Biotherapeutics, Inc.
Company
Silence Therapeutics plc
Company
Keenova Therapeutics plc
Company
NORTHWEST BIOTHERAPEUTICS INC
Company
Dianthus Therapeutics, Inc. /DE/
Company
BioXcel Therapeutics, Inc.
Company
First Tracks Biotherapeutics, Inc.
Company
Lakewood-Amedex Biotherapeutics Inc.
Company
PLIANT THERAPEUTICS, INC.
Company
Bicara Therapeutics Inc.
Company
Bambusa Therapeutics, Inc.
Company
PTC THERAPEUTICS, INC.
Company
Beam Therapeutics Inc.
Company
Primary record5
BEACON TOPCO, INC. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. Amendment to the Merger Agreement As previously disclosed, on September 29, 2025, Beacon Topco, Inc., a Delaware corporation (“ Topco ”), entered into an Agreement an
BEACON TOPCO, INC. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. Amendment to the Merger Agreement As previously disclosed, on September 29, 2025, Beacon Topco, Inc., a Delaware corporation ( Topco ), entered into an Agreement and
Barinthus Biotherapeutics plc. filed SCHEDULE 13G/A
0001856079-26-000003.txt : 20260911 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001856079 XXXXXXXX LIVE 1 American Depositary Shares, each representing one Ordinary Share 09/09/2026 0001828185 Barinthus Biothe
Barinthus Biotherapeutics plc. filed 4
SEC form 4 filed by Barinthus Biotherapeutics plc. (CIK 1828185) on 2026-09-09.
Barinthus Biotherapeutics plc. filed 8-K
Item 1.02 Termination of a Material Definitive Agreement. The information set forth in the Introductory Note of this Current Report on Form 8-K is incorporated herein by reference. In connection with the effectiveness of